168 related articles for article (PubMed ID: 35645805)
41. Glycosylation of Sodium/Iodide Symporter (NIS) Regulates Its Membrane Translocation and Radioiodine Uptake.
Chung T; Youn H; Yeom CJ; Kang KW; Chung JK
PLoS One; 2015; 10(11):e0142984. PubMed ID: 26599396
[TBL] [Abstract][Full Text] [Related]
42. Rutin Scavenges Reactive Oxygen Species, Inactivates 5'-Adenosine Monophosphate-Activated Protein Kinase, and Increases Sodium-Iodide Symporter Expression in Thyroid PCCL3 Cells.
Gonçalves CFL; de Freitas ML; Fortunato RS; Miranda-Alves L; Carvalho DP; Ferreira ACF
Thyroid; 2018 Feb; 28(2):265-275. PubMed ID: 29160164
[TBL] [Abstract][Full Text] [Related]
43. Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter.
Petrich T; Helmeke HJ; Meyer GJ; Knapp WH; Pötter E
Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):842-54. PubMed ID: 12111124
[TBL] [Abstract][Full Text] [Related]
44. A probasin promoter, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for radiovirotherapy of prostate cancer.
Trujillo MA; Oneal MJ; McDonough S; Qin R; Morris JC
Gene Ther; 2010 Nov; 17(11):1325-32. PubMed ID: 20428214
[TBL] [Abstract][Full Text] [Related]
45. In silico screening and in vivo experimental validation of 15-PGDH inhibitors from traditional Chinese medicine promoting liver regeneration.
Feng C; Qiao C; Ji W; Pang H; Wang L; Feng Q; Ge Y; Rui M
Int J Biol Macromol; 2024 Jun; 274(Pt 1):133263. PubMed ID: 38901515
[TBL] [Abstract][Full Text] [Related]
46. Blood Profiles in the Prediction of Radioiodine Refractory Papillary Thyroid Cancer: A Case-Control Study.
Liu H; Chen Q; Liu B; Wang J; Chen C; Sun S
J Multidiscip Healthc; 2023; 16():535-546. PubMed ID: 36879649
[TBL] [Abstract][Full Text] [Related]
47. Gut Microbiome and Radioiodine-Refractory Papillary Thyroid Carcinoma Pathophysiology.
Samimi H; Haghpanah V
Trends Endocrinol Metab; 2020 Sep; 31(9):627-630. PubMed ID: 32273149
[TBL] [Abstract][Full Text] [Related]
48. MAPK Inhibitors Enhance HDAC Inhibitor-Induced Redifferentiation in Papillary Thyroid Cancer Cells Harboring
Fu H; Cheng L; Jin Y; Cheng L; Liu M; Chen L
Mol Ther Oncolytics; 2019 Mar; 12():235-245. PubMed ID: 30847387
[TBL] [Abstract][Full Text] [Related]
49. Molecular radiotheragnostics in thyroid disease.
Singh N; Lewington V
Clin Med (Lond); 2017 Oct; 17(5):453-457. PubMed ID: 28974598
[TBL] [Abstract][Full Text] [Related]
50. HMGB1-mediated autophagy regulates sodium/iodide symporter protein degradation in thyroid cancer cells.
Chai W; Ye F; Zeng L; Li Y; Yang L
J Exp Clin Cancer Res; 2019 Jul; 38(1):325. PubMed ID: 31331356
[TBL] [Abstract][Full Text] [Related]
51. Construction of an MUC-1 promoter driven, conditionally replicating adenovirus that expresses the sodium iodide symporter for gene therapy of breast cancer.
Trujillo MA; Oneal MJ; Davydova J; Bergert E; Yamamoto M; Morris JC
Breast Cancer Res; 2009; 11(4):R53. PubMed ID: 19635153
[TBL] [Abstract][Full Text] [Related]
52. [Sodium iodide symporter in physiology and diseases -- the current state of knowledge].
Wolny M; Syrenicz A
Endokrynol Pol; 2007; 58(6):512-21. PubMed ID: 18205108
[TBL] [Abstract][Full Text] [Related]
53. A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancer.
Smith VE; Read ML; Turnell AS; Watkins RJ; Watkinson JC; Lewy GD; Fong JC; James SR; Eggo MC; Boelaert K; Franklyn JA; McCabe CJ
J Cell Sci; 2009 Sep; 122(Pt 18):3393-402. PubMed ID: 19706688
[TBL] [Abstract][Full Text] [Related]
54. [
Jiang H; DeGrado TR
Theranostics; 2018; 8(14):3918-3931. PubMed ID: 30083270
[TBL] [Abstract][Full Text] [Related]
55. A Novel Orally Active Inverse Agonist of Estrogen-related Receptor Gamma (ERRγ), DN200434, A Booster of NIS in Anaplastic Thyroid Cancer.
Singh TD; Song J; Kim J; Chin J; Ji HD; Lee JE; Lee SB; Yoon H; Yu JH; Kim SK; Yoon GS; Hwang H; Lee HW; Oh JM; Lee SW; Lee J; Choi HS; Na SY; Choi WI; Park YJ; Song YS; Kim YA; Lee IK; Cho SJ; Jeon YH
Clin Cancer Res; 2019 Aug; 25(16):5069-5081. PubMed ID: 31010838
[TBL] [Abstract][Full Text] [Related]
56. Clinical, Pathological, and Molecular Profiling of Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Shobab L; Gomes-Lima C; Zeymo A; Feldman R; Jonklaas J; Wartofsky L; Burman KD
Thyroid; 2019 Sep; 29(9):1262-1268. PubMed ID: 31319763
[No Abstract] [Full Text] [Related]
57. The Thyroid Na+/I- Symporter: Molecular Characterization and Genomic Regulation.
Alotaibi H; Tuzlakoğlu-Öztürk M; Tazebay UH
Mol Imaging Radionucl Ther; 2017 Feb; 26(Suppl 1):92-101. PubMed ID: 28117294
[TBL] [Abstract][Full Text] [Related]
58. [β-catenin nuclear translocation represses thyroid cancer stem cells differentiating into cells with sodium-iodine symporter functional expression].
Lan L; Deng W; Cui D; Chen HL; Huo LL; Zuo QY; Li W; Zhang GY; Luo Y
Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1904-1910. PubMed ID: 31269588
[No Abstract] [Full Text] [Related]
59. Clinical and biologic roles of PDGFRA in papillary thyroid cancer: a study based on immunohistochemical and in vitro analyses.
Shi L; Chen H; Qin YY; Gan TQ; Wei KL
Int J Clin Exp Pathol; 2020; 13(5):1094-1107. PubMed ID: 32509085
[TBL] [Abstract][Full Text] [Related]
60. Alpha-lipoic acid induces sodium iodide symporter expression in TPC-1 thyroid cancer cell line.
Choi HJ; Kim TY; Ruiz-Llorente S; Jeon MJ; Han JM; Kim WG; Shong YK; Kim WB
Nucl Med Biol; 2012 Nov; 39(8):1275-80. PubMed ID: 22995901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
